BACKGROUND Malignant insulinoma occurs in a few patients with insulinoma. Due to the
small sample of patients, there are little data regarding their clinical manifestation as well as …

Background The cardiovascular safety and efficacy of many current antihyperglycemic agents,
including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. Methods We …

The recent success of pancreatic islet transplantation has generated considerable
enthusiasm. To better understand the quality and characteristics of human islets used for …

The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase
glucose-dependent insulin secretion, enhance insulin gene transcription, expand islet cell mass, …

Background— Diabetes mellitus and heart failure frequently coexist. However, few diabetes
mellitus trials have prospectively evaluated and adjudicated heart failure as an end point. …

The complexity and costs associated with traditional randomized, controlled trials have
increased exponentially over time, and now threaten to stifle the development of new drugs and …

Objectives Hemoptysis, an important and alarming symptom, often indicates serious disease.
This study was designed to assess the different causes of hemoptysis, the relative …

OBJECTIVE Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. …

ContextSolitary pancreas transplantation (ie, pancreas alone or pancreas-after-kidney) for
diabetes mellitus remains controversial due to procedure-associated morbidity/mortality, …

OBJECTIVE This study compared the efficacy and safety of dual add-on of saxagliptin plus
dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 …